This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Industry Veteran Bill Vaughan Joins Remedi SeniorCare® To Elevate Education And Consulting Throughout The LTC Industry

BALTIMORE, April 25, 2013 /PRNewswire/ -- Remedi SeniorCare ® has named Bill Vaughan as the new Vice President of Education and Clinical Affairs. In this new role, Vaughan will serve as a key clinical resource for Remedi customers, partners and industry professionals. He will work to further Remedi's footprint throughout the industry, contributing thought leadership through educational and consulting engagements at key venues, Remedi pharmacies and in the media.

(Logo:  http://photos.prnewswire.com/prnh/20130425/PH02001LOGO )

"Bill has been an important part of the Maryland healthcare community for over 30 years," said Michael Bronfein, Remedi's Chairman and CEO. "Our customers, our colleagues and our industry look to his unparalleled experience as a state LTC surveyor and the Chief Nurse of Maryland's Office of Health Care Quality. We are very pleased and very fortunate to have him join the Remedi team and look forward to his leadership and deep expertise in clinical practices and regulations."

Vaughan's area of focus will include the promotion of Remedi's innovative, leading-edge pharmacy solutions – including Paxit ® automated medication dispensing – in conjunction with industry best practices to address the complex clinical and regulatory challenges in long-term care. He will also work with Remedi customers and partners to improve the regulatory oversight of healthcare facilities and advance person-centered care across the board.

Mr. Vaughan recently retired after a 25 year career with Maryland's regulatory agency, the Office of Health Care Quality. After spending 14 years as a Health Facility Surveyor, he was promoted to Chief Nurse of the Office in 2001. In this position, he provided clinical guidance and oversight to the agency's 120 surveyors. Prior to his work with the state, Vaughan held various leadership roles in nursing. He received his Bachelor of Science in Nursing at the University of Maryland at Baltimore.

About Remedi SeniorCare

Remedi SeniorCare ®, a leading-edge pharmacy provider, enables long-term care facilities to deliver better business results and provide exceptional resident-centered care. At the forefront of implementing high-tech advancements for the industry, Remedi redefined medication administration and management with the launch of the Paxit ® automated medication dispensing system, delivering superior accuracy, efficiency and medication cost reduction.  Remedi's online and electronic tools via My Remedi ® web portal and Connexit electronic data interchange further drive business management efficiency and overall cost reduction.  Remedi supports more than 30,000 residents across nine states and Washington, D.C. with RapidResponse SM customer service, ensuring prompt access to medication delivery, expertise and comprehensive support. For more information, visit www.RemediRx.com.

SOURCE Remedi SeniorCare

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs